Reply to “Financial hindrances to introducing higher-valent pediatric combination vaccines”

Aodi Huanga National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China;b National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information

Xia Xua National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China;b National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information

Lin Tanga National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China;b National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information

Fuzhen Wanga National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China;b National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, ChinaCorrespondence[email protected]
View further author information

Reply to “Financial hindrances to introducing higher-valent pediatric combination vaccines”

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reply to “Financial hindrances to introducing higher-valent pediatric combination vaccines”

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date